Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 20 years or older (or adult age as defined by local rules) at the time of signing consent
- People who have an advanced solid tumour confirmed by laboratory testing of tissue or cells (Part 1 of the trial), or people who have non-small cell lung cancer (NSCLC) with a specific HER2 gene mutation confirmed by a central laboratory test (Part 2 of the trial)
- People in Part 2 only: those whose cancer can be measured using standard imaging criteria (called RECIST 1.1)
- People whose general health and ability to carry out daily activities meets a specific score — either a score of 0 or 1 for Part 1, or 0 to 2 for Part 2 (confirm with trial site what these scores mean for eligibility)
- People whose heart, liver, kidneys, and other organs are functioning well enough to meet the trial's requirements
- People considered a suitable candidate for experimental treatment by their treating doctor
Who may not be able to join:
- People with known active or untreated cancer that has spread to the brain or the lining around the brain or spinal cord
- People in Part 2 only: those who have previously been treated with certain targeted therapies that act on the EGFR or HER2 proteins (called TKIs)
- People with a serious active or ongoing infection
- People who have recently received a live-virus vaccine
- People who have received cancer treatment or other experimental therapy within the past 28 days, or within a timeframe based on how long the previous treatment stays active in the body
- People who have not yet recovered from side effects of previous cancer treatment (side effects must have reduced to a mild level or resolved)
- People who have had major surgery within 28 days before starting the trial
- People who have had another separate cancer diagnosis within the past 2 years
- People with a significant or clinically relevant heart condition, or whose heart electrical reading (called QTcF interval) is 470 milliseconds or longer
- People with significant digestive system problems that could affect how the trial drug (ABT101) is absorbed by the body
- People with a known history of alcohol or drug abuse
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +886-2-2742-1839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the recommended Phase 2 Dose (RP2D) of ABT-101 in Part 1; Determine antitumor activity based on Objective Response Rate (ORR) in Part 2 in patients with NSCLC with targeted mutation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.